Who are 129-Xe's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hyperpolarized xenon 129.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/129-xe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

129-Xe — Competitive Intelligence Brief

129-Xe (129-Xe) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hyperpolarized gas contrast agent. Area: Pulmonary/Respiratory.

marketed Hyperpolarized gas contrast agent Pulmonary/Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

129-Xe (129-Xe) — Children's Hospital Medical Center, Cincinnati. 129-Xe is a hyperpolarized xenon-129 gas used as a contrast agent for magnetic resonance imaging (MRI) to visualize lung ventilation and gas exchange.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
129-Xe TARGET	129-Xe	Children's Hospital Medical Center, Cincinnati	marketed	Hyperpolarized gas contrast agent
Hyperpolarized xenon 129	Hyperpolarized xenon 129	Y. Michael Shim, MD	marketed	Hyperpolarized gas contrast agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hyperpolarized gas contrast agent class)

Children's Hospital Medical Center, Cincinnati · 1 drug in this class
Y. Michael Shim, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 129-Xe — Competitive Intelligence Brief. https://druglandscape.com/ci/129-xe. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab